The corrective phase is near completion. Fibonacci Levels: 0.5 and 0.618 retracement zones crucial. Solana (SOL) shows signs ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

The zodiacal light shines in the evening as the Moon reaches Last Quarter and skims past Spica and Antares in the sky this ...

According to the EPA, it remains on track to complete its Phase-1 work by the end of the month. The speed of the work has ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

From Love’s Travel Stops across the nation to Priester’s Pecans in Alabama, electric charging projects across the country ...

Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.

The page may have been moved or deleted. You can try searching for it below, move on or ask for help.

Swedish biotech company Gesynta Pharma AB has secured $27million in a Series B financing round led by Innovestor Life Science in Finland.